Vostally (ramipril) oral solution
Approval Date: Jul 2025
Indicated for the treatment of hypertension to lower blood pressure, in patients 55 and older to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes, and in patients with post-myocardial infarction heart failure to reduce risk of death and hospitalization
Sdamlo (amlodipine) oral solution
Approval Date: Jul 2025
Indicated alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension or coronary artery disease
Xarelto® (rivaroxaban) tablets
Approval Date: May 2025
Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns. In March, a 2.5 mg dose of this generic was approved; this approval applies to 10 mg, 15 mg, and 20 mg doses
Xarelto® XR (rivaroxaban) extended-release tablets
Approval Date: Jun 2025
Indicated to reduce the risk of stroke, major cardiovascular events in patients with coronary artery disease, and for the treatment of several other cardiovascular concerns
Yutrepia™ (treprostinil) inhalation powder
Approval Date: May 2025
Indicated for the treatment of pulmonary arterial hypertension, this is the first and only dry-powder formulation of treprostinil
Arbli (losartan potassium) oral suspension
Approval Date: Mar 2025
Indicated for the treatment of hypertension, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic neuropathy in certain type 2 diabetes patients with hypertension
Tezruly™ (terazosin) oral solution
Approval Date: Jul 2024
Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate
Entresto® (sacubitril and valsartan) tablets
Approval Date: May 2024
Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure
Winrevair™ (sotatercept-csrk) injections
Approval Date: Mar 2024
A first-in-class biologic indicated for the treatment of pulmonary arterial hypertension to increase exercise capacity and reduce the risk of clinical worsening events
Opsynvi® (macitentan and tadalafil) tablets
Approval Date: Mar 2024
Indicated for the treatment of pulmonary arterial hypertension, both in patients who are treatment naïve or who are already on an ERA, PDE5 inhibitor or both
Tryvio™ (aprocitentan) tablets
Approval Date: Mar 2024
Indicated for the treatment of hypertension in combination with other antihypertensive drugs to lower blood pressure
Katerzia® (amlodipine benzoate) oral suspension
Approval Date: Jun 2023
For the treatment of hypertension and coronary artery disease
Inpefa™ (sotagliflozin) tablets
Approval Date: May 2023
Indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes
Byvalson™ (nebivolol and valsartan) tablets
Approval Date: Sep 2022
Indicated for the treatment of hypertension, to lower blood pressure
Edarbi® (azilsartan medoxomil) tablets
Approval Date: Jul 2022
Indicated for the treatment of hypertension to lower blood pressure